Tab%252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary/gastrointestinal excretion. ## Primary Indications Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing Standard dose: 5 mg orally once daily. Maximum dose: 5 mg/day. ## Pediatric Dosing Safety and efficacy have not been established in patients <18 years of age. Use in pediatrics is off-label and typically managed by pediatric endocrinologists. ## Dose Adjustments * **Renal Impairment:** No dosage adjustment indicated (metabolized via non-renal pathways). * **Hepatic Impairment:** No dosage adjustment indicated. * **Geriatric:** No dosage adjustment indicated. ## Contraindications * Hypersensitivity to linagliptin. * History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to DPP-4 inhibitors. ## Adverse Effects * **Common:** Nasopharyngitis, hypoglycemia (when used with secretagogues or insulin). * **Serious:** Acute pancreatitis (post-marketing reports), severe arthralgia (joint pain), bullous pemphigoid, and hypersensitivity reactions. ## Key Drug Interactions * **Strong P-gp/CYP3A4 Inducers (e.g., Rifampin):** May decrease linagliptin exposure, potentially reducing efficacy. Monitor glycemic control if co-administration is necessary. * **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; consider dose reduction of the secretagogue or insulin. ## Monitoring * **HbA1c:** Checked at least twice yearly in patients meeting treatment goals, or quarterly if not at goal. * **Renal function:** Periodically monitor, though not strictly required for dose titration. * **Clinical:** Watch for signs of pancreatitis (persistent severe abdominal pain), joint pain, or skin lesions. ## Clinical Pearls * **Renal Advantage:** Unlike saxagliptin or sitagliptin, linagliptin requires no renal dose adjustments, making it a preferred DPP-4 inhibitor in chronic kidney disease. * **Administration:** May be taken with or without food. * **Pancreatitis:** If pancreatitis is suspected, discontinue immediately and do not restart. * **Weight:** Considered weight-neutral. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines may vary by institution or region. Always verify current prescribing information, dosing, and safety considerations via official package inserts or recognized clinical databases (e.g., Lexicomp, UpToDate) before prescribing or administering medication.